AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Health experts say they are disappointed and confused by the flurry of suspensions of the coronavirus vaccine developed by Oxford-AstraZeneca.

Doctors baffled by suspension of AstraZeneca vaccine over blood clot fears

The chief executive of AstraZeneca - whose COVID-19 vaccine has been temporarily suspended in several European countries - is "on a hot seat and knows it", said French Industry Minister Agnes Pannier-Runacher.

French Industry Minister: AstraZeneca CEO is 'on a hot seat'

AstraZeneca PLC (LON:AZN) announced that it has modified an existing agreement with the US Government to supply up to 500,000 additional doses of AZD7442, billing it an extra US$205mln. The drug is a long-acting antibody (LAAB) combination for the prevention and treatment of COVID-19, currently being tested in late-stage trials in more than 9,000 participants around the world.

AstraZeneca extends US agreement for COVID-19 treatment candidate

Issues around the AstraZeneca-Oxford vaccine could hurt global trade — that's bad news for Asia, said Steve Cochrane, chief APAC economist at Moody's Analytics.

AstraZeneca vaccine halt could slow down Asia's economic recovery, says economist

Germany, Italy, and France joined the list of countries that have suspended the use of AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine over reports of blood clots in some recipients, as per Reuters. What Happened: Denmark and Norway stopped giving the shot last week after reporting a couple of cases of bleeding, blood clots, and a low platelet count.

Germany, France Join List Of Countries Suspending AZN's COVID-19 Vaccine; WHO Urges Not To Halt Vaccinations

The nations said they suspended the vaccine as a cautionary step, as regulators continued to investigate reports of blood clots in a small number of people who received it.

Germany, France, Italy Join Countries In Suspending Use Of AstraZeneca Vaccine Over Blood Clot Concerns

AstraZeneca's (LON: AZN) COVID-19 vaccine that it developed in collaboration with the University of Oxford recently came under fire after reports of blood clots in some patients. On Monday, Ireland, Germany, and the Netherlands announced to have suspended the use of the vaccine on fears of such dire such effects.

Ireland, Germany, and the Netherlands suspend use of AstraZeneca's COVID-19 vaccine

France joins list of European countries suspending AstraZeneca vaccine use

AstraZeneca (AZN) announces analysis of safety data of more than 17 million people vaccinated with its vaccine, demonstrating no increased risk of blood clot.

AstraZeneca (AZN) Defends COVID-19 Vaccine Safety With Data

AstraZeneca has said there is no increased risk of blood clots from its Covid-19 vaccine, as the Netherlands and Ireland joined a fast-growing list of European countries suspending inoculations.

AstraZeneca Defends Vaccine After More Countries Suspend Its Use

AstraZeneca insisted Sunday that its COVID-19 vaccine is safe in its firmest rebuttal yet to concerns over its safety that have led to seven countries suspending its use. Some national health authorities — mainly in Europe — have stopped using the shot while they investigate whether it could be linked to instances of blood clots in people who took it.

AstraZeneca insists its COVID-19 vaccine is safe and there is no link to blood clots, as 7 countries suspend its use

AstraZeneca has found no evidence that its COVID-19 vaccine increases the risk of blood clots like those that led several countries to halt their rollout of the shot. The British drugmaker tried to quell safety concerns after blood clots emerged in some people who had been vaccinated, prompting about a dozen nations to stop using.

AstraZeneca finds no evidence COVID vaccine raises blood clot risk

The UK government is scrambling to pour cold water on fears that AstraZeneca's COVID-19 vaccine causes blood clots. The vaccine was developed by Oxford University, and authorized in the UK last December. Prime Minister Boris Johnson, Health Minister Matt Hancock hailed it at the time as a feat of British resolve and skill.

UK politicians, who hailed the AstraZeneca vaccine as a national victory, are scrambling to calm fears over blood clots

The Netherlands and Ireland become the latest countries to pause the rollout of the AstraZeneca vaccine as a precautionary measure.

AstraZeneca defends COVID-19 vaccine after more countries suspend its use over blood clot concerns

The Netherlands has paused the use of AstraZeneca's COVID-19 vaccine as a precaution while investigators look into cases of blood clots among vaccinated people. Dutch health minister Hugo de Jonge said Sunday that the suspension would last at least two weeks, as the country awaits further guidance from the European Medicines Agency (EMA), the European regulator.

The Netherlands becomes the 7th country to suspend AstraZeneca's COVID-19 vaccine, pending an investigation into blood clots

The WHO has sought to downplay safety concerns, saying last week that there is no link between the shot and an increased risk of developing blood clots.

Ireland, Netherlands become latest countries to suspend AstraZeneca vaccine

AstraZeneca PLC's (LON:AZN) has defended its COVID-19 vaccine after it was suspended in the Netherlands and the Republic of Ireland. The Dutch government said the decision was taken as a precaution and the halt will last until March 29.

AstraZeneca defends COVID-19 vaccine after new suspensions in Netherlands, Republic of Ireland

Netherlands and Ireland joined several other countries who have temporarily suspended the rollout of the shots after reports of side effects including blood clots.

AstraZeneca Defends Covid-19 Vaccine Safety As The Netherlands, Ireland Join Others In Suspending Use

AstraZeneca Plc (NASDAQ: AZN) said on Sunday that a review of safety data of more than 17 million people vaccinated with its COVID-19 vaccine in the European Union and the United Kingdom showed no evidence of an increased risk of blood clots. What Happened: According to the drugmaker, the safety data showed no evidence of an increased risk of pulmonary embolism, deep vein thrombosis (DVT) or thrombocytopenia, in any defined age group, gender, batch or in any particular country.

AstraZeneca Review Finds COVID-19 Vaccine Doesn't Increase Risk Of Blood Clots

NEW YORK, March 14, 2021 /PRNewswire/ -- NOTICE: Previous releases about this case cited an incorrect lead plaintiff deadline of March 27. The actual deadline is March 29.

ALERT - LEAD PLAINTIFF DEADLINE CORRECTION: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AstraZeneca plc of Class Action Lawsuit and Upcoming Deadline - AZN

Ireland is the latest country to suspend the use of the AstraZeneca vaccine temporarily.  What Happened: Many European countries now have suspended the use of AstraZeneca Plc (NASDAQ: AZN) COVID-19 vaccines after reports of blood clotting problems.

Countries Piling In To Suspend AstraZeneca Vaccine Over Blood-Clotting Concerns

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In AstraZeneca To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - March 14, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ:AZN) and reminds investors of the March 29, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in AstraZeneca stock or options between May...

AstraZeneca Class Action Reminder

The World Health Organization has urged countries to keep inoculating citizens with AstraZeneca and Oxford University's COVID-19 vaccine as it investigates reports that some people developed blood clots after getting the shot. The agency's Friday statement came as multiple countries paused their use of the vaccine as authorities investigate cases of blood clots found among people who were inoculated with it.

The WHO says countries should keep using AstraZeneca's COVID-19 vaccine as it investigates reports of blood clots

Moderna

Was AstraZeneca Smart to Sell Its Moderna Shares?

NEW YORK, March 12, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AstraZeneca PLC (NASDAQ: AZN) between May 21, 2020 and November 20, 2020, inclusive (the "Class Period"), of the important March 29, 2021 lead plaintiff deadline.

News for AstraZeneca Stock (AZN)